Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTI-0102 in mild to moderate TBI and PTSD
NCT04262895Phase 2Withdrawn
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cysteamine-pantetheine disulfide in traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), sponsored by VA Office of Research & Development. Planned start Oct 2021; status: withdrawn.
02
Drugs
cysteamine-pantetheine disulfide
03
Conditions
traumatic brain injury (TBI)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04262895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262895.